Travere licenses BTK inhibitor civorebrutinib for $112.5M upfront, up to $1.03B in milestones
Filed June 2, 2026 · Period ending June 1, 2026 · ~1 min read
5 material changes detected in this filing.
Create a free account to read the full summary — it takes 30 seconds.
Partner
Trade TVTX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Generated by AI · Jun 3, 2026 4:09 PM